GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (OTCPK:ESALF) » Definitions » Price-to-Owner-Earnings

Eisai Co (Eisai Co) Price-to-Owner-Earnings : 88.90 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Eisai Co Price-to-Owner-Earnings?

As of today (2024-04-26), Eisai Co's share price is $40.005. Eisai Co's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.45. It's Price-to-Owner-Earnings for today is 88.90.


The historical rank and industry rank for Eisai Co's Price-to-Owner-Earnings or its related term are showing as below:

ESALF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.19   Med: 7.27   Max: 1631.27
Current: 89.83

During the past 13 years, the highest Price-to-Owner-Earnings of Eisai Co was 1631.27. The lowest was 3.19. And the median was 7.27.


ESALF's Price-to-Owner-Earnings is ranked worse than
87.65% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.64 vs ESALF: 89.83

As of today (2024-04-26), Eisai Co's share price is $40.005. Eisai Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.21. Therefore, Eisai Co's PE Ratio for today is 33.17.

As of today (2024-04-26), Eisai Co's share price is $40.005. Eisai Co's EPS without NRI for the trailing twelve months (TTM) ended in was $1.21. Therefore, Eisai Co's PE Ratio without NRI for today is 33.17.

During the past 13 years, Eisai Co's highest PE Ratio without NRI was 89.62. The lowest was 4.20. And the median was 10.00.


Eisai Co Price-to-Owner-Earnings Historical Data

The historical data trend for Eisai Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Price-to-Owner-Earnings Chart

Eisai Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.32 6.94 10.59 17.55 518.64

Eisai Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.77 518.64 - 1,835.33 104.26

Competitive Comparison of Eisai Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Eisai Co's Price-to-Owner-Earnings falls into.



Eisai Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Eisai Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=40.005/0.45
=88.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eisai Co  (OTCPK:ESALF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Eisai Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Eisai Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (Eisai Co) Business Description

Traded in Other Exchanges
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (Eisai Co) Headlines

From GuruFocus